Ultragenyx Pharmaceutical and Kyowa Kirin International (KKI), a subsidiary of Kyowa Hakko Kirin (Kyowa Hakko Kirin), have reported positive 64-week data from a pediatric Phase 2 study of burosumab (KRN23) for X-linked hypophosphatemia (XLH) treatment in children aged between five and 12 years.
Allergan announced to advance its wrinkle treatment Botox to third phase after its phase II study showed a partial benefit in treating patients with major depressive disorder (MDD).
Verona Pharma has enrolled and dosed the first patient in a Phase 2a clinical study to evaluate RPL554, as a treatment option for cystic fibrosis (CF).
Amgen and UCB have released results from the fourth year of a Phase 2 study demonstrating the safety and efficacy of a second course of treatment with evenity (romosozumab), an investigational candidate for postmenopausal women with osteoporosis.
Ritter Pharmaceuticals' lactose intolerance treatment, RP-G28, demonstrated efficacy and clinically meaningful benefit in phase 2b/3 clinical trial.
Summit Therapeutics has announced that, subject to regulatory approval, it will go ahead with the planned extension phase of PhaseOut DMD, a Phase 2 clinical trial studying the utrophin modulator ezutromid.
Akashi Therapeutics has secured approval from the US Food and Drug Administration (FDA) to resume clinical development of HT-100 (delayed-release halofuginone) in patients with any of the genetic mutations that cause Duchenne muscular dystrophy (DMD).
A phase 3 study of Lilly’s breast cancer drug, abemaciclib, in combination with fulvestrant, has met its primary endpoint of progression-free survival (PFS).
Nektar Therapeutics’ NKTR-181 has met primary and secondary endpoints in phase 3 SUMMIT-07 study in chronic pain.
Novartis has unveiled results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes indicating that Entresto (sacubitril/valsartan) tablets enahanced glycemic control, as evaluated by hemoglobin A1c (HbA1c) testing, compared to ACE-inhibitor enalapril.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.